Screening 160,000 Peptides to Find the Best Natural ACE Inhibitors for Blood Pressure

Computational molecular docking of all 160,000 possible tetrapeptide combinations against the ACE enzyme structure. Top candidates were validated with in vitro ACE inhibition assays (IC50 measurements). Molecular interaction analysis identified the chemical bonds driving inhibition. A proof-of-concept experiment introduced tryptophan residues into a naturally tryptophan-free protein to test the predictive power of the findings.

ACE inhibitor drugs are among the most prescribed medications worldwide for hypertension. Food-derived ACE-inhibitory peptides offer a natural, lower-side-effect alternative, but finding effective sequences has been largely trial and error. This systematic computational approach screens the entire tetrapeptide space at once, revealing clear design rules (tryptophan is king) that could accelerate discovery of functional food peptides for blood pressure management.

This study represents the growing intersection of computational biology and functional food science. Rather than randomly testing food-derived peptides, researchers can now predict which sequences will be most active. The strong role of tryptophan could influence how food scientists design functional foods and supplements targeting blood pressure — and may partly explain why certain protein-rich diets are associated with cardiovascular benefits.

Molecular docking is a computational prediction — actual biological activity can differ. The IC50 values are from in vitro enzyme assays, not from human blood pressure studies. Bioavailability (whether these peptides survive digestion and reach the bloodstream intact) was not tested. The 90% ACE inhibition from engineered protein was in vitro, not in an animal or human model.